Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.
What happened
FDA inspected the firm's API plant in Indrad, Gujarat, from April 13 to 17, 2026, and found layered unidentified residues, corroded equipment, improperly gowned staff including one in open-toed sandals, and no written cleaning or maintenance procedures. Investigators also could not find raw data, notebooks, or printouts to show that testing reported on certificates of analysis had actually been done, and found stability chambers powered off and tadalafil stability samples missing. The firm recalled all its U.S.-distributed APIs on August 4, 2026, and FDA placed its drugs on Import Alert 66-40 on August 11, 2026.
What FDA found
Production rooms and shared equipment were covered in unidentified residues and rust, and an employee wore open-toed sandals in front of open processing lines where APIs are handled.
FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)There were no written cleaning or maintenance procedures, cleaning was never checked by swab or rinse testing, and the same equipment was used for multiple APIs.
Certificates of analysis reported test results, but the firm could not show any raw data, lab notebooks, or equipment printouts proving the tests were run, and it did not name the contract lab that performed some testing.
Stability chambers were switched off or outside temperature and humidity limits, records supporting the labeled expiry dates were missing, and scheduled tadalafil stability samples could not be located.
The quality unit did not qualify contract labs, validate manufacturing, calibrate equipment, test incoming materials, do annual product reviews, or assess cross-contamination risk on non-dedicated equipment.
What FDA wants
FDA tells the firm to remediate the facility, cleaning program, laboratory documentation, stability program, and quality unit, and to send a written response with evidence of completed corrections and a CAPA plan to CDER within 15 business days. FDA also recommends hiring a qualified CGMP consultant to do a six-system audit before the firm seeks resolution of its compliance status.
Who should pay attention
- compounding pharmacies that bought these APIs
- drugmakers and brands that source APIs from Indian plants
- firms listing this site as a manufacturer on applications or supplements
This is a summary. Read the original letter on fda.gov.